• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>Cancer Medicine >Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized single-blinded crossover study
【2h】

Efficacy of triplet regimen antiemetic therapy for chemotherapy-induced nausea and vomiting (CINV) in bone and soft tissue sarcoma patients receiving highly emetogenic chemotherapy and an efficacy comparison of single-shot palonosetron and consecutive-day granisetron for CINV in a randomized single-blinded crossover study

机译：三联疗法止吐疗法对接受高度呕吐化疗的骨和软组织肉瘤患者化疗诱导的恶心和呕吐（CINV）的疗效以及单次帕洛诺司琼和连续一日Granisetron在随机单药治疗中的疗效比较盲交叉研究

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

The first aim of this study was to evaluate combination antiemetic therapy consisting of 5-HT3 receptor antagonists, neurokinin-1 receptor antagonists (NK-1RAs), and dexamethasone for multiple high emetogenic risk (HER) anticancer agents in bone and soft tissue sarcoma. The second aim was to compare the effectiveness of single-shot palonosetron and consecutive-day granisetron in a randomized, single-blinded crossover study. A single randomization method was used to assign eligible patients to the palonosetron or granisetron arm. Patients in the palonosetron arm received a palonosetron regimen during the first and third chemotherapy courses and a granisetron regimen during the second and fourth courses. All patients received NK-1RA and dexamethasone. Patients receiving the palonosetron regimen were administered 0.75 mg palonosetron on day 1, and patients receiving the granisetron regimen were administered 3 mg granisetron twice daily on days 1 through 5. All 24 patients in this study received at least 4 chemotherapy courses. A total of 96 courses of antiemetic therapy were evaluated. Overall, the complete response CR rate (no emetic episodes and no rescue medication use) was 34%, while the total control rate (a CR plus no nausea) was 7%. No significant differences were observed between single-shot palonosetron and consecutive-day granisetron. Antiemetic therapy with a 3-drug combination was not sufficient to control chemotherapy-induced nausea and vomiting (CINV) during chemotherapy with multiple HER agents for bone and soft tissue sarcoma. This study also demonstrated that consecutive-day granisetron was not inferior to single-shot palonosetron for treating CINV.
机译：这项研究的第一个目的是评估由5-HT3受体拮抗剂，神经激肽1受体拮抗剂（NK-1RAs）和地塞米松组成的联合止吐疗法对骨骼和软组织肉瘤中多种高致癌风险（HER）抗癌药的作用。第二个目的是在随机，单盲交叉研究中比较单次帕洛诺司琼和连续日格拉司琼的有效性。使用一种随机方法将符合条件的患者分配给帕洛诺司琼或格兰司琼组。帕洛诺司琼组的患者在第一和第三疗程中接受了帕洛诺司琼方案，在第二和第四疗程中接受了格拉司琼方案。所有患者均接受NK-1RA和地塞米松治疗。接受帕洛诺司琼方案的患者在第1天给予0.75 mg帕洛诺司琼，接受格拉司琼方案的患者在第1至5天每天两次给予3mg格拉司琼。本研究中的所有24名患者均接受了至少4个化学疗程。总共评估了96个疗程的止吐疗法。总体而言，完全缓解的CR率（无催吐发作且不使用急救药物）为34％，而总控制率为（CR加无恶心）为7％。单次帕洛诺司琼和连续日格拉司琼之间未观察到显着差异。在多种骨和软组织肉瘤的多种HER药物化疗期间，使用3种药物联合进行止吐治疗不足以控制化疗引起的恶心和呕吐（CINV）。这项研究还表明，连续治疗的格拉司琼在治疗CINV方面不逊于单次帕洛诺司琼。

著录项

相似文献

  • 外文文献
  • 中文文献
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号